Subcutaneous injection of H2 is a novel effective treatment for type 2 diabetes

Chuang Wang, Fangyan Wang, Haifeng Xu, Jiaming Liu, Keke Jin, Mimi Kong, Qingyi Wang, Xiaolong Zhang, Zhengzheng Zhang, Zhuang Zhang

Read more:

DOI: 10.1111/jdi.12674 DOI is the universal ID for this study.

This link will take you to the full study.


Aims/introduction: In previous studies H2 administration has clearly shown effectiveness in inhibiting diabetes. Here, we evaluated whether subcutaneous injection of H2 shows enhanced efficacy against type 2 diabetes mellitus (T2DM) induced in mice by a high-fat diet and low dose streptozotocin (STZ) treatment. Material and methods: H2 was injected subcutaneously at a dose of 1ml/mouse/week for four weeks. T2DM associated parameters were then evaluated to determine the effectiveness of subcutaneous H2 administration.

Results: The body weight of H2 -treated mice did not change over the course of the experiment. Compared to the untreated control animals, glucose, insulin, low-density lipoprotein (LDL) and triglyceride (TG) levels in serum were significantly lower in treated mice, while high-density lipoprotein cholesterol (HDL) in the serum was significantly higher. Glucose tolerance and insulin sensitivity were both improved in H2 -treated mice. Diabetic nephropathy (DN) analysis showed significant reductions in urine volume, urinary total protein and β2 microglobulin, kidney/body weight ratio and kidney fibrosis associated with subcutaneous injection of H2 . Conclusions: Subcutaneous injection of H2 significantly improves T2DM and DN related outcomes in a mouse model, supporting further consideration of subcutaneous injection as a novel and effective route of clinical H2 administration. This article is protected by copyright. All rights reserved.

Publish Year 2017
Country China
Rank Positive
Journal Journal of Diabetes Investigation
Primary Topic Whole Body
Secondary TopicDiabetes (Type II)
Model Mouse
Tertiary TopicGlucose Metabolism
Vehicle Gas
pH N/A
Application Injection